Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: A systematic review and meta-analysis of randomized-controlled trials

• Main Authors: Srisurapanont,M., Suttajit,S., Maneeton,N., Maneeton,B.
• Format: Article
• Published: Elsevier Limited 2015
• Subjects: Arts and Humanities (miscellaneous); Biological Psychiatry; Psychiatry and Mental Health
• Online Access: http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84924289206&origin=inward; http://cmuir.cmu.ac.th/handle/6653943832/38419
• Institution: Chiang Mai University

© 2015 Elsevier Ltd. Limited options are available for clozapine-resistant schizophrenia and intolerable side effects of clozapine. We conducted a systematic review of randomized-controlled trials (RCTs) to determine the efficacy and safety of aripiprazole augmentation of clozapine for schizophrenia. Electronic databases searched included PubMed, Scopus, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Web of Science. This review synthesized the data of four short-term (8-24 weeks), placebo-controlled trials (N=347). The overall relative risk (RR, 95% confidence interval) of discontinuation rates was not significantly different between groups (RR=1.41, 95% CI=0.78to2.56). The pooled standardized mean differences (SMDs, 95% CIs) (Z-test; number of study; I2-index) suggested trends of aripiprazole augmentation benefits on overall psychotic [-0.40 (-0.87 to 0.07) (n=3; Z=1.68, p=0.09; I2=68%)], positive [-1.05 (-2.39 to 0.29) (n=3; Z=1.54, p=0.12; I2=94%)], and negative [-0.36 (-0.77 to 0.05) (n=3; Z=1.74, p=0.08; I2=54%)] symptoms. Despite of no benefit on three cardiometabolic indices (i.e., fasting plasma glucose, triglyceride, and high-density lipoprotein), aripiprazole augmentation was superior for weight change with a mean difference (95% CI) of-1.36kg (-2.35 to-0.36) (n=3; Z=2.67, p=0.008; I2=39%) and LDL-cholesterol with a mean difference of-11.06mg/dL (-18.25 to-3.87) (n=3; Z=3.02, p=0.003; I2=31%). Aripiprazole augmentation was not correlated with headache and insomnia but significantly associated with agitation/akathesia (RR=7.59, 95% CI=1.43 to 40.18) (n=3; Z=2.38, p=0.02; I2=0%) and anxiety (RR=2.70, 95% CI=1.02 to 7.15) (n=1; Z=2.00, p=0.05). The limited short-term data suggested that aripiprazole augmentation of clozapine can minimize the cardiometabolic risk, causes agitation/akathesia, and may be effective in attenuating psychotic symptoms.